MetaCap

Enanta Pharmaceuticals Inc. (ENTA)

NASDAQ: ENTAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

7.62-0.36 (-4.51%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ENTA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$222.19M
EPS (TTM)
-$2.35
52-week range
7.56 – 17.15
Day range
7.56 – 8.06
Volume / Avg
457.63K / 287.81K
Beta
—

52-week range

$7.56$17.15

ENTA stock today

Shares of Enanta Pharmaceuticals (ENTA) finished lower on Nov 20 at $7.62, a drop of 4.51% or $0.36 per share, versus the S&P 500's 3.70% decline. At this level, ENTA sits near the bottom of its 52-week range of $7.56 to $17.15: 55.6% below the high, set on Dec 29, 2025 and 0.8% above the low. ENTA is down 51.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 40.1%.

Enanta Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$2.35), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Enanta Pharmaceuticals

Company profile

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Jay R. Luly Ph.D.
Headquarters
Watertown, MA
Employees
120
IPO year
2013
Website
enanta.com

Financial highlights

Full financials

In fiscal 2026, Enanta Pharmaceuticals generated $63.0 million in revenue, down 3.6% from fiscal 2025, its first annual decline since 2025. Enanta Pharmaceuticals reported a net loss of $68.2 million, compared with a loss of $81.9 million a year earlier. Operating margin was -99.0%.

Enanta Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue$63.00M$65.32M$67.64M$79.20M$86.16M
Growth-3.56%-3.42%-14.61%-8.07%-11.24%
Net income$-68.25M$-81.89M$-116.05M$-133.82M$-121.75M
EPS (diluted)$-2.35$-3.84$-5.48$-6.38$-5.91

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$21.83+186.48%

  • Strong buy 1
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $19.00High $32.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.87 vs $-0.83
Surprise
-4.82%

ENTA news

All ENTA news

Enanta Pharmaceuticals peers

Health Care sector
ENTA peer companies
CompanyPrice% ChgMarket capCompare
IMRXImmuneering Corporation Class A3.38-2.03%$218.90Mvs ENTA
RCKTRocket Pharmaceuticals Inc.1.95-7.58%$217.74Mvs ENTA
KROSKeros Therapeutics Inc.11.08-2.72%$217.44Mvs ENTA
PYXSPyxis Oncology Inc.1.81+7.74%$216.49Mvs ENTA
ARCTArcturus Therapeutics Holdings Inc.7.45-1.97%$214.73Mvs ENTA
CYPHCypherpunk Technologies Inc.1.41-18.02%$210.15Mvs ENTA
VNDAVanda Pharmaceuticals Inc.3.45-6.13%$208.32Mvs ENTA
CAMPCAMP4 Therapeutics Corporation3.79-5.25%$237.84Mvs ENTA

Indexes, lists and sector

Enanta Pharmaceuticals stock FAQ

What is Enanta Pharmaceuticals's stock price today?

ENTA last traded at $7.62 as of Nov 20, 4:00 PM EST, down 4.51% on the day. Prices are delayed at least 15 minutes.

Who is Enanta Pharmaceuticals's CEO?

Dr. Jay R. Luly Ph.D. is the chief executive officer of Enanta Pharmaceuticals Inc., which has about 120 employees.

What is the ENTA 52-week high?

The 52-week high for ENTA is $17.15 and the 52-week low is $7.56. The stock is currently 55.6% below its high.

Compare ENTA